reSee.it - Related Video Feed

Video Saved From X

reSee.it Video Transcript AI Summary

In the presented remarks, the speaker engages the audience with a series of questions intended to reveal potential overlaps among health sector entities. The questions ask the audience to raise their hands if their companies own or control a health insurance division; if they also employ health care providers or own clinics, specialty pharmacies, or any other medical practice or pharmacy; if they own or control a pharmacy benefit manager (PBM); and if they lead a publicly traded company at which they have a legal responsibility to maximize shareholder value. These questions are designed to surface the breadth of influence held by large health care firms. The speaker asserts that the audience’s responses demonstrate a broader pattern: the largest health insurance companies are not limited to providing insurance alone. Instead, they are also involved in delivering medical services and operating pharmacies. The speaker notes that these entities diagnose and decide treatment for patients, indicating an active role in clinical decision-making beyond underwriting risk or processing claims. Further, the speaker highlights that these same large insurers are also PBMs, describing PBMs as “another form of middlemen managing drug benefits.” This point emphasizes a layered structure in which a single company can influence which drugs are preferred, covered, or reimbursed, thereby affecting patient access and pricing across the drug supply chain. The speaker concludes that these combined roles signify that large health insurers are “increasingly controlling every aspect of our health care system.” This characterization suggests a consolidation of functions—from coverage and care provision to drug benefit management—under a few dominant corporate entities. In summary, the speaker’s lines of inquiry and subsequent claims illustrate a perceived convergence: health insurance companies are simultaneously insurers, medical providers, pharmacies, and PBMs, and they are expanding their control over multiple facets of health care delivery and economics. The overarching assertion is that the largest players in the health care landscape occupy a multifaceted, integrated position that spans diagnosis, treatment decisions, pharmacy operations, and drug benefit management, contributing to a broader phenomenon of comprehensive control within the system.

Video Saved From X

reSee.it Video Transcript AI Summary

The transcript discusses several intertwined points about the FDA's funding, information sources, and a personal health journey. It states that the FDA gets 47% of its funding from the pharmaceutical industry, and that this information was released only after a rumor claimed 50% of their funding came from big pharma. The speaker notes, “the people that you’re supposed to be making rules and regulations for are the same people that are paying you money,” describing this as a conflict of interest and urging readers to consider the implication of funding influencing regulatory decisions. The speaker then shifts to their personal experience with health issues and the challenge of finding valid information that isn’t paid for by big pharma. They share a statistic attributed to women with similar issues: “85 to ninety percent of the women who experience the same issues that I experience notice changes in their symptoms or alleviation completely from their symptoms simply by changing their diet, namely going gluten free.” Although the speaker says they personally are not inclined to adopt gluten-free changes, they are cutting out refined carbs and sugars from their diet and report progress: “I've been on this diet for two days now, and I already feel a ton different.” This personal anecdote is presented in the context of comparing diet-driven symptom changes to pharmaceutical influence. The speaker mentions ongoing changes to their living space and routines as part of their broader stance. They say, “we're putting up our squat rack again in our home gym,” signaling a strengthening or lifestyle shift. They also report, “we did get some egg laying birds,” suggesting new household activities. Throughout, there is a reiterated sentiment directed at big pharma: “basically saying a big to big pharma,” underscoring their stance against pharmaceutical influence. Finally, the speaker emphasizes the surprising nature of the 47% funding figure and reiterates, “I still can't believe it's 47% of their funding, and they think that's okay.” They invite audience engagement, closing with, “as always, I look forward to hearing your thoughts about all of this down below.”

Video Saved From X

reSee.it Video Transcript AI Summary

Let's discuss UnitedHealthcare, particularly in light of its recent leadership changes. Last year, they generated $373 billion in revenue, with 60% coming from their pharmacy benefit manager, a largely unknown entity. The public and politicians often overlook the significant role of health insurance companies, which I mentioned on Rogan. While there's a lot of focus on Big Pharma, which made about $600 billion, health insurance companies generated 2.5 times that amount, totaling $1.5 trillion. Projections indicate they could reach $1.9 trillion in revenue by 2029.

Video Saved From X

reSee.it Video Transcript AI Summary

COVID vaccines are government property. A leaked letter from Anthem Blue Cross Blue Shield revealed doctors could earn a quarter million bonus for vaccinating 70% of patients. Money flows from the government to insurance companies, who profit from vaccine distribution. CVS and Walgreens likely receive government funds for administering vaccines.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker discusses the pharmaceutical industry and its problems. They explain that the industry has struggled to keep up with the complexity of molecular biology and the changing face of capitalism. The speaker highlights how the industry has become powerful and profitable by increasing prices and creating "me too" drugs. They criticize the lack of transparency and the influence of the industry on decision-making at various levels. The speaker emphasizes the need for better pharmacovigilance and a change in medical education to prioritize understanding the dangers of medications. They also address concerns about the industry and the role of doctors.

Video Saved From X

reSee.it Video Transcript AI Summary

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Video Saved From X

reSee.it Video Transcript AI Summary

It used to be that pharmaceutical companies were working with the doctors. Now unfortunately, companies are captured by the price of the stock. Know, venture capitalist owned pharmaceutical companies. They owned the CR or the clinical research organizations. They owned the site. They owned the institutional review board. They owned the advertising, the marketing. They influenced through the media. And so unfortunately, there's a big it's a it's a loaded question, but it's a big market. And what we saw this pandemic was the price of the stock mattered more than the price of a life.

Video Saved From X

reSee.it Video Transcript AI Summary

Pediatricians may be incentivized to administer vaccines due to revenue structures. One article claims that 50% of pediatricians' revenue comes from vaccines. Insurance companies like Blue Cross allegedly pay bonuses to pediatricians who maintain a 95% vaccination rate among their clients. This bonus structure may disincentivize pediatricians from accommodating alternative vaccination schedules, potentially leading them to dismiss patients who request them. These incentives may prevent doctors from prioritizing patient care due to financial considerations. The speaker claims that twenty years ago, 20% of doctors worked for corporations, but now 80% do, and these corporations prioritize revenue over patient well-being.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the existing system was fair, even though the reasons why were not well understood. The speaker claims to have figured out the reasons behind this.

Video Saved From X

reSee.it Video Transcript AI Summary

We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

Video Saved From X

reSee.it Video Transcript AI Summary

The people involved in drug companies, insurance companies, and the food industry work together, often holding stock in each other’s companies and serving on each other’s boards. The transcript describes this as a “criminal enterprise” and outlines one way it allegedly works. In the food industry’s meetings, food companies discuss adding ingredients and claim their chemists understand that each additive, in minute amounts, does not cause problems and has no long-term negative effects when consumed. The account then says that when three additives are combined, a new compound forms that leads to leg twitching or shaking. It may take three to five to seven years to develop because the effects impact nerves. The transcript describes the conversation as follows: the food companies would knowingly begin adding these ingredients because, years later, they expect hundreds of thousands or millions of people to develop symptoms and need treatment. They would propose labeling the condition—restless leg syndrome—when it emerges. The drug companies would then be prompted to have an approved drug ready by that time to generate major profits. It also claims that drug companies work toward these future “epidemics” by developing drugs in advance, contributing to the emergence of illnesses presented as widespread—such as psoriasis, diabetes, hypertension, restless leg syndrome, irritable bowel syndrome, and other conditions said to not have existed fifty years earlier. The transcript links these conditions to advertising campaigns where, if someone experiences twitching, they are told to take another drug. It describes the response as “take another drug.” Finally, insurance companies are said to become involved by figuring out how to profit. The transcript claims that through lobbyists, they work out deals so insurance and government-funded programs effectively pay for the drugs, citing Medicare and Medicaid in the United States. It says similar arrangements exist in other countries and concludes that these groups “make their money” through coordinated actions.

Video Saved From X

reSee.it Video Transcript AI Summary

Speaker 0 and Speaker 1 discuss the COVID-19 vaccine episode, challenging why the vaccine was pursued as a public health solution and exploring deeper incentives behind the program. - A knowledgeable figure at the stand answered a burning question: did they know the vaccine wouldn’t be effective from the start and could be dangerous? The answer given was that it was “a test of a technology.” The exchange suggests the broader aim was testing an entire program of control previewed in Event 2019. - They ask whether inoculation was necessary on billions, noting it could have been tested on a much smaller population. If shots had been basically empty or inert, the data could have been spun to claim success and end the pandemic, preventing injuries from appearing. The absence of that approach remains a mystery. - The speakers point to high pre-vaccine seroprevalence in 2020, including studies from South Dakota showing 50-60% seroprevalence before vaccine release, implying that a saline shot or no shot could have achieved “indomicity” (immunity) without a vaccine. - They discuss why people might fear vaccines and interpret the broader impact: the public is waking up to something terrible having occurred, as it revealed readiness to lie, potential data quality concerns, and risk to pregnant women and healthy children who might get little justification for risk. - The disease’s lethality is framed as greatest among the very old or very sick; for others, it was less deadly, with natural evolution potentially reducing vulnerability over time. - The mRNA platform was touted as a means to outrun mutations, but the timeline to release was still insufficient to stay ahead of natural change. They note accelerated development was the fastest vaccine in history, from detection to inoculation, reducing the timeline by about a year or two, yet not fast enough. - Political and logistical factors delayed release; there is mention that it would not have appeared under Trump and that Eric Topol argued to delay the rollout. Fauci reportedly sent Moderna back to trials due to insufficient racial diversity in participants. - The discussion questions whether the vaccine qualifies as a normal consumer product, given ongoing subsidies, mandates, indemnifications, wartime-like supports, and propaganda. They wonder if there has been an ongoing two-century revolt by industry against public scrutiny, with public interest repeatedly leading to pushback and rebranding. - A central theme is the sophistication of pharma: the “game of pharma” involves owning an IP-based health claim, crafting supportive research, convincing it is safe and effective, achieving standard-of-care status, securing mandates and government funding, and leveraging ongoing propaganda. They describe pharma as a long-running arms race with deep institutional knowledge, implying that it is far more capable of shaping reality than the public realizes.

Video Saved From X

reSee.it Video Transcript AI Summary

Speaker 0: The pharmacy benefit managers. Speaker 1: Think of it like this. So you go to a restaurant and you order a burger. Okay? And let's say that burger costs $15. But before your order goes through, some guy steps in and says, hold on. If the restaurant wants to sell you that burger, they need to pay me $5. And if not, you can't have the burger. Speaker 0: Think of them as the toll bridge between you and drug prices. Speaker 1: But the PBM isn't just collecting the toll. They're also controlling which cars can pass. They own the bridge. They set the price of gas. They use their contracts to profit off of everyone crossing. Speaker 1: So the PBM charges the employer a very high price. It pays the pharmacy a very low price, and it keeps the difference, and that's called spread pricing.

Video Saved From X

reSee.it Video Transcript AI Summary

The FTC sued the largest three PBMs. The FTC accuses these three companies for artificial inflating insulin prices, investigating their rebate system. There were marked up specialty drugs for cancer, HIV, and other conditions by over $7,300,000,000. One of the companies actually countersued the FTC over false and defamatory statements. PBMs own the insurance companies, and the pharmacies. Caremark owns CVS. Express Scripts owns a home delivery pharmacy. Rx owns Optum home delivery pharmacy, so they can ship directly to your house. Control of 80% of all the medications in The US comes from three of the biggest PBMs. In reality, the PBMs are not just the middleman. Since they've merged with the insurance companies and the pharmacies, now they're the actual gatekeepers of medicine.

Video Saved From X

reSee.it Video Transcript AI Summary

A health insurance CEO was recently murdered, sparking surprising support for the act among some younger people, reflecting deep-seated anger towards insurance companies. The discussion highlights how these companies profit from chronic diseases by delaying care and prioritizing profit over patient health. The insurance model has shifted from personal care to a profit-driven system, leading to inadequate patient interactions and a focus on prescription drugs rather than preventative measures. The conversation also touches on the role of pharmacy benefit managers (PBMs) as profit centers for insurers, contributing to rising healthcare costs. Advocates argue for a shift towards proactive, preventative care, emphasizing the need for transparency and accountability in the healthcare system to address chronic diseases effectively.

Video Saved From X

reSee.it Video Transcript AI Summary

The people involved in drug companies, insurance companies, and the food industry work together, with many holding stock in each other’s companies and serving on boards across companies. The transcript describes this as a “criminal enterprise” and explains one example of how it works. The food industry proposes adding multiple ingredients or additives to food. According to the description, each additive by itself, in minute amounts, does not cause any problem, and does not have long-term negative effects when consumed separately. The meeting conversation then turns to how, when all three additives are combined, they form a new compound that leads to leg twitching or shaking. The onset is described as sometimes taking three to five to seven years because it affects nerves. The food companies allegedly discuss the strategy: they plan to start putting the additives in food, anticipating that years later hundreds of thousands or millions of people will develop the leg-shaking issue and will seek treatment. The issue is described as being named “restless leg syndrome.” The drug companies are said to work on a medication in advance so that once the condition becomes widespread, they will have an approved drug ready to sell. The transcript also claims this pattern appears in other conditions, stating that when “an epidemic” occurs—such as psoriasis, diabetes, hypertension, restless leg syndrome, irritable bowel syndrome, and other newly described diseases—drug companies create or market treatments for symptoms and prescribe additional drugs, including when a person taking a drug experiences twitching. Insurance companies are described as then seeking ways to make money and allegedly involve the government through lobbyists. The transcript says they arrange for taxpayer-funded payment for the drugs through insurance coverage, citing Medicare and Medicaid in America, and says similar arrangements occur in other countries. In the transcript’s account, the combined actions of the food industry, drug companies, and insurance companies—backed by government payment—are presented as a recurring method of making money.

Video Saved From X

reSee.it Video Transcript AI Summary

Big Tech, Big Pharma, and Big Finance are all involved in promising that data will improve our healthcare, making it more convenient, affordable, and keeping us healthier. However, global organizations and governments are also entering this space. The future of healthcare lies in the digitalization of the system, which is essential as our healthcare systems will eventually collapse without it. It's remarkable how similar the messages from politics, business, science, and media are. Is this really just about our health, or could there be other interests at play?

Video Saved From X

reSee.it Video Transcript AI Summary

Most physicians and clinicians avoid getting involved in the issue of profit-driven healthcare. The real problem lies in the collusion between academic institutions, doctors, medical journals, and industry for financial gain. These corporations, as legal entities, often exhibit psychopathic traits, prioritizing profit over the well-being of patients. Many top drug companies have been fined billions for illegal marketing, hiding harm data, and manipulating results. However, these fines are often outweighed by the profits they make from selling the drugs. While the pharmaceutical industry has contributed life-saving treatments, the net effect of their practices is negative, with a significant amount of wasted resources and harmful drugs approved.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker points out that major media outlets like CNBC, Fox, and CNN are owned by Vanguard and BlackRock, who are also the top shareholders of Pfizer, Johnson and Johnson, and Moderna. They mention that Vanguard and BlackRock are also the top shareholders of flight companies and junk food manufacturers. The speaker suggests that this control extends to social media platforms like Meta, Snapchat, Twitter, and Google, which they claim are pushing the same narrative as the media. They emphasize that these companies are profit-driven.

Video Saved From X

reSee.it Video Transcript AI Summary

A health insurance CEO was murdered, sparking a surprising reaction among younger people, with 41% expressing support. This reflects a deep-seated anger towards insurance companies, which many believe contribute to America's chronic disease crisis by prioritizing profits over patient care. The discussion highlights the profit-driven nature of health insurance, particularly through pharmacy benefit managers (PBMs), which inflate drug prices and create barriers to necessary care. The system favors medication over preventative measures, leading to widespread chronic illness. Advocates emphasize the need for a shift towards proactive healthcare that focuses on prevention and transparency, rather than a reliance on prescription drugs. The conversation underscores the urgent need for reform in the healthcare system to prioritize patient well-being over corporate profits.

Video Saved From X

reSee.it Video Transcript AI Summary

According to the speaker, 50% of pediatricians' revenue comes from vaccines, with insurance companies like Blue Cross offering bonuses for high vaccination rates, potentially influencing doctors' recommendations. The speaker claims that pediatricians may dismiss families who want alternative vaccine schedules to protect these bonuses. The speaker alleges that 80% of doctors now work for corporations focused on revenue over patient care, creating pressure to generate funds due to medical school debt. The speaker suggests the entire system is incentivized to keep people sick, not necessarily deliberately, but through financial incentives. Insurance companies allegedly profit more from a sick population because they collect money as friction, taking a cut of revenues. The speaker claims that doctors, hospitals, and pharmaceutical companies also benefit financially from people being sick, creating systemic pressure regardless of individual intentions.

Video Saved From X

reSee.it Video Transcript AI Summary

Trump recently announced plans to break up pharmacy benefit managers (PBMs), which are often misunderstood. PBMs were created in the 1970s to help lower prescription drug costs but have since been acquired by major insurance companies, turning them into profit centers. Instead of negotiating lower prices, PBMs negotiate higher costs to receive kickbacks from drug manufacturers. For example, 30% of the cost of drugs like Ozempic goes to PBMs as kickbacks. UnitedHealthcare generated $373 billion in revenue last year, with 60% from its PBM. While insurance companies may not have as high profit margins as big pharma, they use various methods to obscure their profits. Overall, health insurance companies generate significantly more revenue than pharmaceutical companies, highlighting the hidden influence of PBMs in the healthcare system.

Keeping It Real

Luigi Mangione's Secret Motives EXPOSED and the Dark Side of Healthcare Power

Guests: Brigham Buhler

reSee.it Podcast Summary

The episode centers on the escalating outcry over healthcare’s structural failures, catalyzed by the case of Luigi Mangione and the broader critique of United Healthcare’s leadership. Brigham Feler, founder of Ways to Well, argues that the crisis is less about individual villains and more about a system that monetizes illness through opaque pricing, aggressive insurance practices, and monopolistic control by Pharmacy Benefit Managers and big insurers. He details how long approval times for surgeries like spinal procedures forces patients toward opioids, creates dependency, and exposes chronic pain patients to a brutal, dehumanizing process that prioritizes profitability over healing. Feler connects the patient experience to high-level incentives and incentives in the pharmaceutical and insurance sectors. He accuses United Healthcare of deploying AI denial programs that rejected up to 90% of claims, notes a DOJ probe into monopoly practices, and highlights how stock-driven decisions can deprioritize patient welfare. The conversation expands into the mechanics of price manipulation— rebates, middlemen, spread pricing, and the influence of PBMs owned by the major insurers—arguing that these schemes drive up costs for individuals, employers, and taxpayers while masking profits behind complex, opaque billing. The guests discuss real-world consequences: delayed care, debt, and bankruptcy amid a system that discourages preventative measures and suppresses alternative, lower-cost care models. The dialogue culminates in a practical call to action: regain sovereignty over health through cash-pay clinics and proactive, predictive care that looks “under the hood” at more than a handful of biomarkers. The hosts advocate for a shift away from sick-care to prevention, critique the incentives that discourage comprehensive testing, and present Ways to Well as a model aiming to democratize access to thorough blood work, personalized nutrition, and AI-assisted health planning. The episode closes on an urgent reminder that meaningful reform will require individuals seeking better care, as well as broader changes to how drugs, doctors, and insurers interact in a system widely perceived as prioritizing profits over people.

Tucker Carlson

Brigham Buhler: UnitedHealthcare CEO Assassination, & the Mass Monetization of Chronic Illness

Guests: Brigham Buhler

reSee.it Podcast Summary

Tucker Carlson discusses the recent murder of a health insurance CEO in New York, highlighting that 41% of younger people express support for the act, which reflects a deeper hostility towards insurance companies. Brigham Buhler emphasizes that while violence is never justified, the insurance industry contributes to a chronic disease crisis in America by prioritizing profit over patient care. He argues that insurance companies profit from delaying care and procedures, which exacerbates health issues. Buhler explains the evolution of health insurance, noting that it began as a means to provide consistent care but shifted to a profit-driven model with the rise of HMOs in the 1980s. He contrasts the personalized care of pre-HMO days with the current system, where doctors spend an average of just six minutes with patients due to insurance constraints. The conversation shifts to pharmacy benefit managers (PBMs), which Buhler describes as unnecessary middlemen that inflate drug prices through kickbacks. He cites examples of how PBMs manipulate drug costs, leading to higher expenses for patients and employers. Buhler reveals that a significant portion of health insurance profits comes from Medicare and Medicaid, with insurance companies negotiating prices based on inflated average wholesale prices. Buhler stresses the need for a shift towards preventative care, arguing that the current system fails to address the root causes of chronic diseases, which are often lifestyle-related. He highlights the importance of comprehensive blood work and proactive health assessments to prevent diseases before they develop. The discussion touches on the opioid crisis, with Buhler sharing personal experiences of how insurance companies incentivize the prescription of addictive medications over non-addictive alternatives. He argues that the healthcare system is designed to profit from chronic illness rather than promote wellness. Buhler expresses hope for reform, particularly with potential changes under Donald Trump and Bobby Kennedy, emphasizing the need for a healthcare system that prioritizes patient outcomes over profits. He advocates for cash-pay clinics that focus on preventative care, allowing patients to take control of their health without the interference of insurance companies.

Keeping It Real

The Disturbing Secrets Behind The Healthcare Industry - with Brigham Buhler

Guests: Brigham Buhler

reSee.it Podcast Summary

The episode features Jillian Michaels and Brigham Buhler discussing a healthcare system they view as corrupted by powerful entities in pharma and insurance. Buhler recounts his arc from a drug rep to founder of Ways to Well and Revive, detailing how Big Pharma and Big Insurance operate as a cartel that denies, delays, and obstructs patient care to protect profits. He argues that patients are frequently steered away from comprehensive, preventive health strategies toward expensive, disease-driven interventions, highlighting the tension between access to care and the realities of a business-first system. The conversation centers on how misaligned incentives drive up costs while undermining outcomes, from bloated drug prices to opaque rebate structures managed by pharmacy benefit managers (PBMs). They delve into compounding pharmacies as a double-edged sword: essential for affordable, personalized medications and often caricatured by critics, yet targeted by litigation from big manufacturers. Buhler explains the rigorous safety standards some compounding shops uphold, including sterile compounding and third-party validations, while noting the broader problem of 510(k) loopholes and insufficient human trials for many medical devices. The pair also scrutinize GLP-1s and the broader trend of overprescribing, arguing that root causes—nutrition, diet, lifestyle—are underexploited levers for health but underfunded by a system geared toward pharmacologic fixes and chronic revenue. They discuss the cost barriers to advanced diagnostics and preventive testing, pharmacogenetic testing, and the role of comprehensive panels in shaping personalized care. Buhler envisions a future where AI-driven monitoring, predictive testing, and cash-pay clinics like Ways to Well empower individuals to take sovereignty over their health, reduce dependence on insurers, and extend healthspan rather than merely chasing disease management. The dialogue also touches RFK, Casey Means, Callie, and a broader movement advocating diet, prevention, and autonomy, urging listeners to invest in proactive health strategies and to scrutinize the incentives shaping modern medicine. The episode closes with a practical note on affordability, stressing that deeper health insights need not be prohibitively expensive and that a comprehensive baseline can be attained for a few hundred dollars yearly. topics Big Pharma, Big Insurance, healthcare cartels, denials and delays, compounding pharmacies, 510k loopholes, FDA oversight, GLP-1s, preventive medicine, nutrition and lifestyle, predictive medicine, AI in healthcare, Ways to Well, Wastewell, pharmacogenetics, healthspan, RFK, Casey Means, Callie otherTopics Bayer and historical drug testing, opioid crisis, Sackler family history, insulin pricing and PBMs, shadow bans in media, the role of regulation in innovation, privacy concerns with AI health monitoring booksMentioned Bottle of Lies